Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Assetmark Inc.

Assetmark Inc. boosted its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 9.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 2,477 shares of the biopharmaceutical company’s stock after purchasing an additional 207 shares during the period. Assetmark Inc.’s holdings in Intra-Cellular Therapies were worth $181,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently added to or reduced their stakes in the stock. Oak Ridge Investments LLC acquired a new stake in shares of Intra-Cellular Therapies in the 2nd quarter worth about $811,000. SG Americas Securities LLC increased its stake in shares of Intra-Cellular Therapies by 962.7% in the second quarter. SG Americas Securities LLC now owns 48,778 shares of the biopharmaceutical company’s stock valued at $3,341,000 after purchasing an additional 44,188 shares during the period. Clearbridge Investments LLC increased its stake in shares of Intra-Cellular Therapies by 12.3% in the first quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company’s stock valued at $120,723,000 after purchasing an additional 191,416 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of Intra-Cellular Therapies by 232.0% during the first quarter. Russell Investments Group Ltd. now owns 50,845 shares of the biopharmaceutical company’s stock valued at $3,519,000 after buying an additional 35,528 shares during the last quarter. Finally, Driehaus Capital Management LLC acquired a new position in shares of Intra-Cellular Therapies during the second quarter worth approximately $14,755,000. 92.33% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, President Michael Halstead sold 22,869 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sharon Mates sold 53,013 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total value of $4,010,433.45. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $80,970,388.85. This represents a 4.72 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 179,471 shares of company stock valued at $13,670,383. 2.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently commented on ITCI. Morgan Stanley raised their target price on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. UBS Group cut their price objective on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. JPMorgan Chase & Co. increased their target price on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. Royal Bank of Canada upped their price target on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. Finally, The Goldman Sachs Group decreased their price objective on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.23.

Intra-Cellular Therapies Stock Performance

Shares of NASDAQ:ITCI opened at $83.42 on Friday. The stock has a market capitalization of $8.84 billion, a price-to-earnings ratio of -95.88 and a beta of 0.97. Intra-Cellular Therapies, Inc. has a 1-year low of $54.17 and a 1-year high of $93.45. The company has a 50 day moving average price of $78.27 and a 200 day moving average price of $74.29.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $175.40 million during the quarter, compared to analyst estimates of $172.30 million. During the same quarter in the previous year, the firm earned ($0.25) earnings per share. The business’s revenue was up 39.0% compared to the same quarter last year. On average, sell-side analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.